Join
Live feed
·
PRReleasevia Quantisnow
Allogene Therapeutics Inc. logo

Allogene Therapeutics Reports Interim Futility Analysis from Pivotal ALPHA3 Trial Showing 58.3% MRD Clearance with Cemacabtagene Ansegedleucel (Cema-Cel) vs. 16.7% in Observation Arm in First-Line Consolidation LBCL

ByQuantisnow·Wall Street's wire, on your screen.
ALLO· Allogene Therapeutics Inc.
Health Care

This insight was delivered by - Wall Street's wire, on your screen. Quantisnow is a real-time market data and news platform for retail investors, aggregating SEC filings, FDA approvals, analyst ratings, insider trading, and press releases into a single customizable feed. Track ALLO (Allogene Therapeutics Inc.) and more on Quantisnow.